跳至主要内容
临床试验/NCT07815379
NCT07815379进行中(未招募)4 期

Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction: A Randomized Clinical Trial

Mansoura University1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2025年10月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
进行中(未招募)
入组人数
140
试验地点
1
主要终点
IPSS change

研究概览

简要总结

Failed medical treatment to alleviate LUTS and AUR is an indication for intervention, some trials were published elucidating the possible use of standard dose tamsulosin and silodosin and double dose tamsulosin but to the best of our knowledge, no studies with head-to-head comparison between Tamsulosin and Combination of Tamsulosin and Silodosin for Management of Lower Urinary Tract Symptoms and Acute Urine Retention in Patients with Benign Prostatic Hyperplasia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Age ≥40 years. Catheterized patients due to acute urine retention secondary to BPO. Patients with moderate and severe LUTS secondary to BPH as proven by IPSS (International Prostate Symptoms score) ≥8 and Qmax <15 ml/sec with total void urine volume >125 cc.

排除标准

  • Patients with neurological problems as: uncontrolled DM, parkinsonism and cerebral stroke.
  • Patients with history of previous prostate surgery. Patients with complicated BPH necessitating intervention as: recurrent/persistent UTI, recurrent hematuria, bladder stones and indwelling urethral catheter due to chromic urine retention (CUR).
  • Patients with suspected malignancy by abnormal Digital Rectal Examination (DRE) and or high PSA.

研究组 & 干预措施

Single alpha blocker for BPH treatment

Placebo Comparator

BPH patients in this arm are given single alpha blocker drug with placebo

干预措施: alpha blocker monotherapy Tamsulosin (Drug)

Double alpha blockers for BPH management

Active Comparator

BPH patients in this arm are given double alpha blocker drugs

干预措施: alpha blockers Tamsulosin and Silodosin (Drug)

结局指标

主要结局

IPSS change

时间窗: 3 months

IPSS score change at 1 and 3 months following drug adminstration

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Abolazm

Consultant

Mansoura University

研究点 (1)

Loading locations...

相似试验